RESUMO
The authors evaluated reparative osteogenesis after incorporation of roncoleukin into combination therapy for experimental drug-resistant tuberculous osteitis. Roncoleukin (12.5 pg/kg, 5 injections, once every 3 days) was used during antituberculosis therapy before and after combined plasty (autobone + OsteoSet-T) in repairing surgical defects. When used in the postoperative period of combined osteoplasty, roncoleukin was shown to contribute to a reduction in the spread of specific inflammatory foci in bone tissue, cessation of an alternative necrotic component, an increase in the rate of osteogenesis with newly formed bone trabeculae, and activation of hematopoietic processes in the bone marrow. In parallel with intensified bone reparative processes, there was immunomodifier-induced stimulation of the absorption and digestion of peritoneal macrophages suppressed in experimental tuberculous osteitis.
Assuntos
Antituberculosos/administração & dosagem , Interleucina-2/administração & dosagem , Osteogênese , Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico , Animais , Medula Óssea/patologia , Regeneração Óssea , Osso e Ossos/efeitos dos fármacos , Osso e Ossos/patologia , Humanos , Interleucina-2/análogos & derivados , Coelhos , Tuberculose Resistente a Múltiplos Medicamentos/patologiaRESUMO
The disability rates and life quality indices were analyzed in 69 patients operated on for active tuberculous coxitis revealed a clear-cut advantage of early radical operations in their complex treatment. Prolongation of the time of surgical interventions results in progression of destructive processes in the affected joint, shows a 2.5-fold increase in the disability rates and drastically reduces the quality of their life.